The combination of avutometinib and defactinib is the first FDA-approved treatment for KRAS-mutated recurrent LGSOC. Approval was based on the phase 2 RAMP-201 trial, showing a 44% overall ...

May 2, 2025 -- The FDA has approved a new treatment for generalized myasthenia gravis (gMG), a disease that causes severe muscle weakness, faster muscle fatigue, and difficulty in speaking and ...

Today, the US Food and Drug Administration (FDA) approved prademagene ... said in its press release announcing approval. The list price for the one-time treatment will be $3.1 million, according ...

The FDA has granted accelerated approval to Verastem’s combination treatment for ovarian cancer. It licensed and has paired two drugs — avutometinib, an MEK inhibitor first developed by Roche ...

April 21, 2025 – The FDA just approved the popular ... This is the seventh approved use for Dupixent and the first new targeted treatment in over a decade for the 300,000 people in the U.S ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY TM (nipocalimab-aahu) for the treatment of ...

Common side effects include elevated lab markers, nausea, fatigue, rash, and various other symptoms affecting multiple body systems. Treatment with the Avmapki Fakzynja Co-pack received accelerated ...